

## UNC CFAR Social and Behavioral Science Research Core SABI Database

**INSTRUMENT TITLE:** *Reduced HIV Concern Scale* 

**SOURCE ARTICLE:** Vanable, P. A., Ostrow, D. G., McKirnan, D. J., Taywaditep, K. J., & Hope, B. A. (2000). Impact of combination therapies on HIV risk perceptions and sexual risk among HIV-positive and HIV-negative gay and bisexual men. Health Psychology, 19(2), 134-145.

## **RESPONSE OPTIONS:**

4-point rating scale, with response options ranging from strongly disagree to strongly agree.

## **SURVEY ITEMS:**

1. The new AIDS combination drugs make me less anxious about unprotected sex.

2. An HIV-positive man whose level of virus in the blood has become undetectable is unlikely to transmit HIV to his partner.

3. It would be more difficult for an HIV-positive person to infect his partner through unsafe sex if he is taking the new drug combination treatments.

4. I am less concerned about having anal sex without a condom now that new drug combination treatments are available.

5. By taking the new drug combinations, an HIV-positive man decreases the chances that he will infect his partners with HTV.

6. I am a lot less worried about sexual "slipping" now that treatments may be given after unprotected sex.

7. I am more comfortable having semen in my mouth now that combination drug treatments are available.

8. Consistent safer sex is less important now that drug combinations may help prevent infection after someone has been exposed to HIV.

## TERMS OF USE:

Individuals may use this information for research or educational purposes <u>only</u> and may not use this information for commercial purposes. When using this instrument, please cite:

Vanable, P. A., Ostrow, D. G., McKirnan, D. J., Taywaditep, K. J., & Hope, B. A. (2000). Impact of combination therapies on HIV risk perceptions and sexual risk among HIV-positive and HIV-negative gay and bisexual men. Health Psychology, 19(2), 134-145.

When presenting results using any survey information you obtained from the SABI, please acknowledge the University of North Carolina at Chapel Hill Center for AIDS Research (CFAR), an NIH funded program P30 AI50410.